卵巢癌患者血浆miRNA水平与顺铂化疗敏感性的相关性研究

目的探讨卵巢癌患者血浆miRNA分子标志物水平与铂类化疗敏感性的相关性。方法应用实时定量PCR方法检测48例卵巢癌患者化疗前后血浆中miRNA的表达，13例体检正常者为内参对照，观察卵巢癌患者铂类化疗药物的疗效及预后的关系。结果初检的11种miRNA中，仅有5种miRNA（miR-124，miR-145，miR-22，miR-106a，miR-142）能够在外周血中检测出。其中3种miRNA（miR-22，miR-106a，miR-142）在正常人和卵巢癌患者的外周血中表达水平比较差异有统计学意义（P＜0．01）。患者化疗后外周血中仅miR-22水平显著升高（约3．2倍），且miR-22水平高者对化疗反应多数敏感，反之不敏感。患者外周血miR-22的表达水平与其预后呈正相关（P＜0．05）。结论血浆中miR-22，miR-106a，miR-142水平升高可能参与了卵巢癌的发生发展，化疗患者敏感者仅miR-22呈高表达，不敏感者miR-22呈低表达，提示其可作为预测化疗敏感性及预后的指标之一。

Study of the relationship between miRNA level in blood plasma of ovarian cancer patients and chemotherapy sensitivity to cispiatin

Objective To investigate the potentiality of specific miRNA level in blood plasma of ovarian cancer patients as a molecular marker to predict sensitivity and response to platinum-based chemotherapy. Methods Quantitative polymerase chain reaction （Q-PCR） was used to check the changing of miRNA level in blood plasma before and after chemotherapy, and explored the relativity between variation and chemotherapy response and clinic outcome. Results Among preliminary screened 11 miRNAs, only 5 miRNAs were able to be detected in peripheral blood. There existed variations in 3 miRNAs （ miR-22, miR-106a, miR-142）. Further detection of the changing of miRNA level in blood plasma before and after therapy, miR-22 was found significantly up-regulated in blood plasma that was underwent platinum-based chemotherapy. Meanwhile, ovarian cancer patients with high miR-22 level were mostly sensitive to platinumbased therapy. Otherwise, miR-22 was positive relative to the clinic prognosis of patients with ovarian cancer. Conclusions miR-22, miR-106a, and miR-142 might participate in the generation and development of ovarian cancer, miR-22 in peripheral blood was probably identified as a novel molecular marker of prediction of the sensitivity to platinum in ovarian cancer patients.